Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital

• DOI: 10.1128/spectrum.01697-22
• Publication Date: 2022-10-03T14:01:41Z
• Authors: C. Weber; T. Schultze; S. Göttig; J. Kessel; A. Schröder; M. Tietgen; S. Besier; T. Burbach; S. Häussler; T. A. Wichelhaus; D. Hack; V. A. J. Kempf; M. Hogardt
• Keywords: Ceftazidime/avibactam; Tazobactam

After testing ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against a collection of 233 multidrug-resistant (MDR) Pseudomonas aeruginosa , we showed that is the most active antipseudomonal β-lactam agent (susceptibility rates were 46.6%, 48.4%, 97.4%, respectively). The prevalent one was sequence type 235 (ST235) (24.7%), followed by ST244, ST175, ST233, with all belonging to top 10 P. high-risk clones worldwide distribution.